Trial Search Results

Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

By using stereotactic body radiation therapy (SBRT) delivered with the Cyberknife system®, the current protocol attempts to mimic or improve the excellent local control rates seen in treatment of early stage breast cancer while attempting to increase convenience, limit invasiveness, decrease toxicity, and improve cosmesis compared to other methods of radiation treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

University of Texas Southwestern Medical Center

Stanford Investigator(s):


  • Radiation: Stereotactic Body Radiation Therapy


Phase 1


Inclusion Criteria:

   - DCIS or invasive ductal, medullary, papillary, mucinous (colloid), or tubular

   - Eligible patients must have appropriate staging studies identifying them as AJCC stage
   T1 or T2 (≤3 cm) treated with lumpectomy and axillary node dissection with at least 6
   nodes sampled or sentinel node biopsy. Patients with up to 3 positive nodes without
   microscopic or macroscopic evidence of extracapsular extension are eligible.

   - The patient's Zubrod performance status must be 0-2.

   - Patients must be ≥ 18 years of age.

   - If chemotherapy is planned, it must begin no earlier than two weeks following
   completion of radiation therapy.

   - Unifocal breast cancer (no evidence of gross multifocal disease, multicentric, or
   bilateral disease.

   - Negative margins after lumpectomy (re-excision for initial positive margins is
   allowed-negative margins defined as >2 mm clear of tumor in all directions).

   - Negative post- lumpectomy mammography if malignancy-associated microcalcifications
   were initially present.

   - The target lumpectomy cavity must be clearly delineated.

   - Patients must complete appropriate pretreatment evaluation, including post-lumpectomy
   mammogram if microcalcifications were initially present to confirm complete removal.

Exclusion Criteria:

   - Evidence of suspicious microcalcifications in the breast prior to start of radiation.

   - Patients with history of collagen vascular disease, specifically dermatomyositis with
   a CPK level above normal or active skin rash, systemic lupus erythematosis, or

   - Patients with 4 or more histologically positive axillary nodes if axillary dissection
   is performed.

   - Patients with distant metastases.

   - Patients with invasive or extensive in-situ lobular carcinoma or non-epithelial breast
   malignancies such as sarcoma or lymphoma.

   - Patients with multicentric gross disease defined as tumors in different quadrants of
   the breast or tumor separated by at least 4 cm or other clinically or radiographically
   suspicious areas in the ipsilateral breast unless confirmed to be negative for
   malignancy or biopsy.

   - Patients must not have any palpable or radiographically suspicious ipsilateral or
   contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes
   unless there is histologic confirmation that these nodes are negative for tumor.

   - Any previously treated contralateral invasive breast carcinoma or synchronous
   contralateral breast carcinoma.

   - Prior non-hormonal therapy or radiation therapy for the current breast cancer or
   hormonal therapy for > 28 days after diagnosis or refusal to discontinue hormonal

   - Patients with Paget's disease of the nipple

   - Patients with prior invasive malignancy (except non-melanomatous skin cancer) unless
   disease free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral
   cavity, or cervix are all permissible).

   - Patients with severe, active co-morbidity.

   - Patients with psychiatric or addictive disorders that, in the opinion of the
   investigator, would preclude obtaining informed consent.

   - Patients who are pregnant or lactating.

   - Previous breast radiation on either side or thoracic radiation on the ipsilateral

Ages Eligible for Study

18 Years - 99 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Katherine Fero
Not Recruiting